Recombinant Human BLMH/Bleomycin Hydrolase Protein，His

Bleomycin hydrolase (BLMH) is acritical enzyme that plays a significant role in the metabolism of bleomycin, an antitumor antibiotic commonly used in cancer therapy. The enzyme is responsible for the hydrolysis of the bleomycin core structure, which converts it into non-toxic metabolites, thereby modulating the drug's efficacy and toxicity. Consequently, understanding BLMH's function and regulation is crucial for optimizing bleomycin treatment regimens and minimizing side effects in patients. Research on recombinant BLMH has gained traction due to advancements in genetic engineering techniques, allowing for the production of large quantities of the enzyme for detailed biochemical studies. These studies aim to elucidate the enzymatic mechanism, substrate specificity, and potential therapeutic applications of BLMH in drug resistance scenarios. Furthermore, recombinant BLMH can serve as a valuable tool in investigating the pharmacogenomics of bleomycin, offering insights into how genetic variations among patients may influence their responses to chemotherapy. Overall, the investigation of BLMH at the molecular level represents a promising area of research that could enhance our understanding of not only bleomycin metabolism but also broader drug resistance mechanisms in cancer therapy.